HuagongsheHuagongshe Chemistry Print Report · For research reference only
2-Methyl-5-(trifluoromethoxy)benzoic acid → 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-(1-{[2-methyl-5-(trifluoromethoxy)phenyl]carbonyl}piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | 2-Methyl-5-(trifluoromethoxy)benzoic acid | HCID 58839058 | — |
| Reactant | 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-piperidin-4-yl-2,4-dihydro-3H-pyrazol-3-one hydrochloride | HCID 66616406 | — |
| Product | 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-(1-{[2-methyl-5-(trifluoromethoxy)phenyl]carbonyl}piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one | HCID 67363066 | — |
Reaction Steps
The title compound is prepared analogously as described for GP2-WU2 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-piperidin-4-yl-2,4-dihydro-3H-pyrazol-3-one (compound B1) and 2-methyl-5-(trifluoromethoxy)benzoic acid (compound F5) as starting compounds. The crude product is purified by chromatography (amino phase silica gel and DCM) and by crystallization from DCM and diethyl ether to yield the title compound.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US09340522B2 |
| Source dataset | uspto-grants-2016_05 |
| ORD ID | ord-2696f2fac8f54d698b18a190d428a37e |
| Source note | uspto-grants-2016_05 |